How should medical device teams implement secure-by-design cybersecurity controls before FDA review?

What secure-by-design means before FDA review

For medical device teams, secure-by-design means the cybersecurity posture is established during design and development, not patched in after validation or during regulatory prep. That matters because pre-market review is easier to support when device identity, update integrity, and cryptographic protections are already part of the architecture rather than retrofitted as compensating controls.

Practically, that shifts the team’s mindset from “can we document security later?” to “can we prove the device was built to resist tampering, unauthorized update paths, and data exposure from the outset?”

Good early design usually includes a trustworthy identity for the device or component, a secure update path with authenticity and integrity checks, and data protection that is appropriate to the clinical and operational environment. Those controls are not just paperwork items, they shape how the device behaves in the field, how it can be serviced safely, and how much residual risk remains when it reaches FDA review. For teams building connected devices or software-driven products, the EU Cyber Resilience Act is a useful external reference point because it reflects the broader product-security direction toward secure-by-design lifecycle expectations.

Which controls matter most in the pre-market build

The strongest baseline is to make security properties intrinsic to the product architecture. Trusted device identity helps distinguish legitimate devices, services, and components from impostors and gives later controls a reliable anchor. Verification of software and firmware updates helps ensure the device only accepts authentic code, which is especially important for products that may be deployed for years and updated remotely.

Strong cryptography should protect sensitive data both at rest and in transit, but teams should treat cryptography as a design discipline, not a checkbox. Key handling, update signing, certificate lifecycle, and trust-store management all affect whether the control is actually dependable in the field. If the device will expose APIs, accept remote commands, or interact with clinical systems, then authentication and integrity controls need to be tested as part of the product, not assumed from the environment.

From a control-selection perspective, the most relevant external implementation guidance is CISA Secure by Design because it reinforces default-secure product thinking, and ISO/IEC 27002:2022 Information Security Controls because it gives teams a practical control-implementation lens for security-by-design work.

How teams can make FDA review easier, not harder

FDA review becomes more manageable when cybersecurity evidence is produced as the product is engineered. The key benefit is traceability: the team can show how security requirements were derived, implemented, tested, and maintained through the development lifecycle. That lowers redesign risk because the team is not discovering fundamental security gaps after design freeze or late-stage verification.

Review readiness also improves when the same architecture decisions support both security and maintainability. For example, if update authenticity, identity trust, and cryptographic protections are built into the system design, those decisions can be documented once and reused across verification artefacts, risk files, and release evidence. By contrast, if security is bolted on late, teams often end up with fragmented evidence, inconsistent assumptions, and higher change cost.

For teams looking for a broader control map, the NIST SP 800-53 Rev. 5 Security and Privacy Controls and CSA Cloud Controls Matrix can help translate design intent into control language where the product includes connected services, data handling, or operational dependencies.

Risk and Threat Considerations

Medical devices that lack secure-by-design controls are exposed to update tampering, unauthorized access paths, data disclosure, and long-lived trust assumptions that become harder to correct after release. The real risk is not only compromise, it is that a weak design can force expensive remediation, delayed approvals, or constrained deployment patterns when the device is already close to market.

Failure mechanism: If device identity is weak, update verification is absent, or cryptographic trust is inconsistent, an attacker or faulty integration can introduce untrusted code, impersonate a legitimate component, or expose sensitive data through the device’s normal operating paths.

Impact: The result can be unauthorized device behavior, reduced confidence in clinical integrity, broader recall or patch pressure, and a harder FDA submission because the team cannot clearly demonstrate that cybersecurity was engineered into the product lifecycle.

Practitioner Guidance

What to prioritise: Start with the controls that define trust at runtime, device identity, update authenticity, and protected data handling. Those are the foundations that later testing, documentation, and review evidence depend on.

What to verify: Confirm that the device can prove what it is, can reject unauthenticated firmware or software, and can protect sensitive data without relying on manual operator behaviour. If any one of those depends on a deployment assumption, treat that as a design gap rather than a documentation task.

Practitioner takeaway: For FDA-facing devices, secure-by-design is about proving trustworthy behaviour early enough that security evidence, engineering evidence, and regulatory evidence all point to the same architecture.

Related resources from NHI Mgmt Group

• How should engineering teams implement secure-by-design and secure-by-default controls under the UK Cybersecurity and Resilience Bill?
• How should security teams implement secure-by-design cryptographic controls for connected products sold in the EU?
• How should security teams implement secure-by-design controls for production AI systems?
• When should organizations review access controls?